Goodpath Launches to Address Unmet Patient Need During COVID-19
At Indicator, we believe that mass personalization and a data-first approach to product transparency will ultimately power the future of ecommerce. This approach is even more powerful when applied to the ‘consumerization’ of healthcare and helping to fill the void of clear guidance or clinical reference points. Currently, more than 70% of U.S. consumers refrain from seeing a primary care physician when dealing with chronic conditions. This stems from the fact that our healthcare system is built more for critical care, not chronic, non-life threatening conditions. When we suffer from chronic back pain or insomnia, for example, we typically visit endless websites and review hundreds of possible remedies. However, nothing is physician-guided and designed for our specific symptoms, especially when it comes to factoring in medical history.
When I first heard about Goodpath, I was impressed by the clear vision and passion of the founders to redefine how people manage chronic health conditions through transparent science and innovative technology. The team is comprised of veteran software entrepreneurs Bill Gianoukos (CEO) and Carl Nehme (COO/CPO) who teamed up with leading medical and healthcare professionals led by Dr. Akl Fahed, a renowned cardiologist and scientist at the Massachusetts General Hospital and Harvard Medical School. Bill previously built and sold two other startups: HeyWire, which sold to SalesForce in 2014, and TrumpIt, which he and Carl sold to Wayfair in 2016. He then went on to work as a Senior Director of Product Management at Wayfair for nearly two years before founding Goodpath. Carl was previously Head of Product at Wayfair where he led a 450-person team responsible for US & International marketplaces.
Patients access Goodpath by taking an online assessment to identify if they are appropriate for treatment on the platform, or whether a more urgent evaluation is warranted by their physician. Then, depending on the patient’s needs, Goodpath uses machine learning to offer a fully integrative solution curated by a multidisciplinary team of physicians, physical therapists, behavioral psychologists, dieticians, pharmacists, trainers, and health coaches. Any solution offered on Goodpath has been vetted to meet rigorous criteria of evidence and safety. Then, depending on the treatment recommendation, Goodpath may recommend various products, supplements or virtual meetings with a dietitian, physical therapist, behavioral health specialist, etc. The approach is based on the model of integrative medicine, which takes account of the whole patient, including all aspects of their lifestyle, triaging of patient acuity, personalization of care, and follow-up and coaching over time without visiting a doctor’s office. The company has already delivered over 30,000 personalized care programs to consumers.
The company has come out of stealth earlier than expected due to coronavirus, which has upended all aspects of the U.S. healthcare system. Goodpath has quickly stepped up to address unmet patient need during this crisis and emerged as a critical solution to keep patients at home and out of the clinic. To that end, Goodpath is offering free trials of its product to all new customers and launched a Coronavirus Advice Page in conjunction with the public launch in an effort to help patients gain access to care amid the pandemic.
We are proud to announce that Indicator Ventures participated in Goodpath’s recent $4M Seed Round led by Global Founders Capital.
To learn more about Goodpath, their plans, and the latest funding round, click here.
